8-((4-(methoxycarbonyl)phenyl)amino)-8-oxooctanoic acid | 1262297-38-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 8-((4-(methoxycarbonyl)phenyl)amino)-8-oxooctanoic acid
• 英文别名: 8-(4-Methoxycarbonylanilino)-8-oxooctanoic acid
• CAS: 1262297-38-0
• 化学式: C₁₆H₂₁NO₅
• 分子量: 307.346
• InChiKey: LXKSVQKBVWTUGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  92.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  8-((4-(methoxycarbonyl)phenyl)amino)-8-oxooctanoic acid 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 、 lithium hydroxide 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 44.0h， 生成
  参考文献：
  名称：

  Cap-Modified Hydroxamate Analogues as Histone Deacetylases Inhibitors and Antitumor Agents

  摘要：

  两系列类似于SAHA的羟肟酸类似物被设计、合成并评估了它们对核HDACs的生物活性。第一系列化合物被发现对PC-3、Hut78、K562和Jurkat E6-1肿瘤细胞系具有非常有效的抑制生长作用，其平均$IC_{50}$值从$0.54{\mu}M$（Ic，Jurkat E6-1）至$7.73{\mu}M$（Ib，K562），表明这些化合物具有细胞通透性，且苯并咪唑基的配体足够柔韧以占据HDAC的结合位点。

  DOI：

  10.5012/bkcs.2014.35.1.129
• 作为产物：
  描述：

  辛二酸 在 乙酸酐 作用下， 以 四氢呋喃 为溶剂， 反应 32.0h， 生成 8-((4-(methoxycarbonyl)phenyl)amino)-8-oxooctanoic acid
  参考文献：
  名称：

  [EN] USE OF CHEMICAL EPIGENETIC MODIFIERS TO MODULATE GENE EXPRESSION
  [FR] UTILISATION DE MODIFICATEURS ÉPIGÉNÉTIQUES CHIMIQUES POUR MODULER L'EXPRESSION GÉNIQUE

  摘要：

  The invention relates to relates to a chemical epigenetic modifier (CEM) comprising compound 1 (AP1867) or a pharmaceutically acceptable salt thereof, a linker, and a chromatin regulatory protein ligand and compositions thereof. The invention also relates to methods for modulating expression of a gene comprising contacting a polynucleotide with a target gene sequence to a fusion protein comprising a FK506-binding protein (FKBP) polypeptide with a F36V mutation and a gRNA binding polypeptide, a gRNA comprising a gene targeting polynucleotide sequence that binds to a target gene sequence and a polynucleotide sequence recognized by the gRNA binding polypeptide, a CEM, and a protein with a DNA binding domain that binds to the target gene sequence and the gRNA, thereby modulating expression of the gene.

  公开号：

  WO2023172889A1

文献信息

• [EN] METAL COMPLEXES HAVING DUAL HISTONE DEACETYLASE INHIBITORY AND DNA-BINDING ACTIVITY<br/>[FR] COMPLEXES MÉTALLIQUES AYANT UNE DOUBLE ACTIVITÉ INHIBITRICE D'HISTONE DÉSACÉTYLASE ET DE LIAISON À L'ADN
  申请人：ROYAL COLLEGE SURGEONS IRELAND

  公开号：WO2011006908A3

  公开（公告）日：2011-03-03
• Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors
  作者：Andrea Milelli、Chiara Marchetti、Eleonora Turrini、Elena Catanzaro、Roberta Mazzone、Daniela Tomaselli、Carmela Fimognari、Vincenzo Tumiatti、Anna Minarini

  DOI：10.1016/j.bmcl.2018.02.034

  日期：2018.4

  Epigenetic modulators Histone deacetylases (HDACs) and Lysine demethylase (LSD1) are validated targets for anticancer therapy. Both HDAC1/2 and LSD1 are found in association with the repressor protein CoREST in a transcriptional co-repressor complex, which is responsible for gene silencing. Combined modulation of both targets results in a synergistic antiproliferative activity. In the present investigation, we report about the design and synthesis of a series of polyamine-based HDACs-LSD1 dual binding inhibitors obtained by coupling Vorinostat and Tranylcypromine. Compound 4 emerged as the most promising of the synthesized series, showing good inhibitory activity towards HDAC1 and LSD1 either in vitro and in cell-based assay (Ki = 42.52 +/- 8.94 nM and IC50 = 3.85 mu M, respectively). Furthermore, at 70.0 mM compound 4 induced a more pronounced cytotoxic effect than Vorinostat (68.6% vs 56.6% of dead cells) in MCF7 cancer cell line. (C) 2018 Elsevier Ltd. All rights reserved.
• METAL COMPLEXES HAVING DUAL HISTONE DEACETYLASE INHIBITORY AND DNA-BINDING ACTIVITY
  申请人：Marmion Celine Josephine

  公开号：US20120190874A1

  公开（公告）日：2012-07-26

  Compounds comprising a metal complex having the structure [X—Y—Z-M n+ ] p+ .B are disclosed in which X is a histone deacetylase inhibitor, M n+ is a DNA-binding heavy metal ion, Y is an aliphatic or aromatic spacer or is absent, and Z is a mono- or bi-dentate or chelating donor linker, or a bridging linker, P+ designates the charge on the complex ion, which may be positive, negative or absent and B is a counterion or is absent. The linker Z is labile and its metal complex X—Y—Z-M n+ is capable of being hydrolysed in-vivo. The compounds find application in the treatment of cancer.
• US8901337B2
  申请人：——

  公开号：US8901337B2

  公开（公告）日：2014-12-02